Myocarditis Associated with Human Parvovirus B-19 Infection in Children: A Case Series of Three Patients During the 2024 European Epidemic and a Brief Literature Review

Authors

  • Emanuele Filice Pediatric Unit, AUSL Bologna, Ospedale Maggiore, Bologna, Italy
  • Arianna Gobbato School of Pediatrics, Alma Mater Studiorum - University of Bologna, Italy
  • Laura Luppi School of Pediatrics, Alma Mater Studiorum - University of Bologna, Italy
  • Nunzia Lisanti School of Pediatrics, Alma Mater Studiorum - University of Bologna, Italy
  • Giulia Menconi School of Pediatrics, Alma Mater Studiorum - University of Bologna, Italy
  • Elena Moccia School of Pediatrics, Alma Mater Studiorum - University of Bologna, Italy
  • Emma Modena School of Pediatrics, Alma Mater Studiorum - University of Bologna, Italy
  • Mattia De Agostini Pediatric Unit, AUSL Bologna, Ospedale Maggiore, Bologna, Italy
  • Francesca Di Florio Pediatric Unit, AUSL Bologna, Ospedale Maggiore, Bologna, Italy
  • Francesca Lombardi Pediatric Unit, AUSL Bologna, Ospedale Maggiore, Bologna, Italy
  • Giacomo Stera Pediatric Unit, AUSL Bologna, Ospedale Maggiore, Bologna, Italy
  • Chiara Ghizzi Pediatric Unit, AUSL Bologna, Ospedale Maggiore, Bologna, Italy

DOI:

https://doi.org/10.12974/2311-8687.2025.13.04

Keywords:

Myocarditis, Parvovirus, b19, pvb19, Children, Erythema infectiosum

Abstract

Background: Human Parvovirus B19 (PVB19) is a globally distributed virus associated with a wide range of clinical manifestations, from mild erythema infectiosum to severe, life-threatening complications including myocarditis. Epidemiological data from early 2024 indicate an increasing prevalence of PVB19 infections in Europe, raising concerns regarding its potential complications in pediatric populations.

Objective: This study describes three pediatric cases of severe PVB19 infection.

Cases presentation: We retrospectively analyzed three cases of PVB19 infection diagnosed at a tertiary care hospital in Bologna, Italy, between March and June 2024 who presented with viral myocarditis. They all required intensive care management, with one patient experiencing cardiac arrest and requiring mechanical ventilation. Despite the severity of their conditions, all three recovered following inotropic support and immunoglobulin therapy. All patients tested positive for PVB19 DNA, and no alternative viral causes were identified.

Conclusions: This case series underscores the wide clinical spectrum of PVB19 infection and its potential for severe, life-threatening complications in pediatric patients. Considering the recent rise in PVB19 cases, clinicians should maintain a high index of suspicion for myocarditis in children presenting with severe symptoms. Early recognition and prompt supportive management are crucial in improving outcomes. Further research may help to better understand PVB19 pathogenesis and develop targeted preventive strategies.

References

Parvoviruses - PubMed. https://pubmed.ncbi.nlm.nih.gov/ 29489222/.

Rogo, L. D., Mokhtari-Azad, T., Kabir, M. H. & Rezaei, F. Human parvovirus B19: a review. Acta Virol 58, 199-213 (2014). https://doi.org/10.4149/av_2014_03_199

Landry, M. L. Parvovirus B19. Microbiol Spectr 4, (2016). https://doi.org/10.1128/microbiolspec.DMIH2-0008-2015

Venturoli, S., Bertoldi, A., Manaresi, E., Lazzarotto, T. & Gallinella, G. Epidemiology of Parvovirus B19 Infection In an Italian Metropolitan Area, 2012-2024: COVID-19 Pre-Pandemic, Pandemic and Post-Pandemic Trends. J Med Virol 97, (2025). https://doi.org/10.1002/jmv.70296

Schultz, J. C., Hilliard, A. A., Cooper, L. T. & Rihal, C. S. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc 84, 1001–1009 (2009). https://doi.org/10.1016/S0025-6196(11)60670-8

Krych, S. et al. Viral Myocarditis as a Factor Leading to the Development of Heart Failure Symptoms, Including the Role of Parvovirus B19 Infection—Systematic Review. International Journal of Molecular Sciences 2024, Vol. 25, Page 8127 25, 8127 (2024). https://doi.org/10.3390/ijms25158127

Dennert, R. et al. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther 15, 193-201 (2010). https://doi.org/10.3851/IMP1516

Molina, K. M. et al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatr Cardiol 34, 390-397 (2013). https://doi.org/10.1007/s00246-012-0468-4

Ferro, V. et al. Severe Outcomes From Suspected Human Parvovirus B19 Infection in Immunocompetent Children: The Need for Timely Recognition. J Med Virol 97, (2025). https://doi.org/10.1002/jmv.70324

Bua, G. et al. Antiviral activity of brincidofovir on parvovirus B19. Antiviral Res 162, 22-29 (2019). https://doi.org/10.1016/j.antiviral.2018.12.003

McCrindle, B. W. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation 135, e927-e999 (2017). https://doi.org/10.1161/CIR.0000000000000484

Robinson, J., Hartling, L., Vandermeer, B., Sebastianski, M. & Klassen, T. P. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev 2020, CD004370 (2020). https://doi.org/10.1002/14651858.CD004370.pub4

d’Humières, C. et al. An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024. Euro Surveill 29, (2024). https://doi.org/10.2807/1560-7917.ES.2024.29.25.2400339

Guillet, M. et al. New atypical epidemiological profile of parvovirus B19 revealed by molecular screening of blood donations, France, winter 2023/24. Eurosurveillance 29, 2400253 (2024). https://doi.org/10.2807/1560-7917.ES.2024.29.21.2400253

Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA. https://www.ecdc.europa.eu/en/publications-data/risks-posed-reported-increased-circulation-human-parvovirus-b19-eueea.

Jiménez Cruz, J. et al. Ongoing outbreak of maternal parvovirus B19 infections in Germany since end of 2023: consequence of COVID-19 pandemic? Ultrasound Obstet Gynecol 65, (2025). https://doi.org/10.1002/uog.29197

Saffioti, C. et al. Outbreak of parvovirus-B19 infection in pregnant women: Is it time to rethink a preconception or first trimester screening? Int J Gynaecol Obstet (2025). https://doi.org/10.1002/ijgo.70057

Takemoto, K. et al. Seroprevalence of eight viruses and pertussis in pregnant women at a regional hospital in Japan in 2022: Comparison with previous studies. Jpn J Infect Dis JJID.2024.307 (2025). https://doi.org/10.7883/yoken.JJID.2024.307

Kociol, R. D. et al. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement from the American Heart Association. Circulation 141, E69-E92 (2020). https://doi.org/10.1161/CIR.0000000000000745

Hazebroek, M. R. et al. Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial. Eur J Heart Fail 23, 302-309 (2021). https://doi.org/10.1002/ejhf.2082

Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002; 2(9): 706-713. https://doi.org/10.1038/nri891

Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol. 2004; 53(Pt 6): 459-475. https://doi.org/10.1099/jmm.0.05485-0

Downloads

Published

2025-09-27

How to Cite

Filice, E. ., Gobbato, A. ., Luppi, L. ., Lisanti, N. ., Menconi, G. ., Moccia, E. ., Modena, E. ., Agostini, M. D. ., Florio, F. D. ., Lombardi, F. ., Stera, G. ., & Ghizzi, C. . (2025). Myocarditis Associated with Human Parvovirus B-19 Infection in Children: A Case Series of Three Patients During the 2024 European Epidemic and a Brief Literature Review . International Journal of Pediatrics and Child Health, 13, 26–30. https://doi.org/10.12974/2311-8687.2025.13.04

Issue

Vol. 13 (2025)

Section

Articles